A Multi-Center, Evaluator -Masked, Randomized, Parallel Group, Active Controlled, Comparative Study of SPARC's SDP-133 Once Daily Compared With Lumigan 0.01% (Bimatoprost Ophthalmic Solution) in Subjects With Open Angle Glaucoma or Ocular Hypertension
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
Most Recent Events
- 26 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Apr 2019 New trial record